Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
(Posted: 06/25/2007, Updated: 05/19/2009) - Patients with localized gastrointestinal stromal tumors (GIST) who took imatinib (Gleevec®) after surgical removal of the primary tumor were less likely to have a recurrence of their cancer, according to findings presented at the 2007 ASCO meeting in Chicago.
Maintenance Rituximab May Improve Survival in Follicular Lymphoma
(Posted: 04/02/2009) - Follicular lymphoma patients who receive maintenance therapy with rituximab after their disease goes into remission may have better survival than those who do not receive such therapy, according to the February 18, 2009, issue of Journal of the National Cancer Institute.
Azacitidine Improves Survival in Myelodysplastic Syndromes
(Posted: 03/26/2009) - The DNA methyltransferase inhibitor azacitidine (Vidaza®) improved overall survival in patients with higher-risk myelodysplastic syndromes, according to the March 2009 issue of Lancet Oncology.
Gabapentin Helps Hot Flashes From Prostate Cancer Treatment
(Posted: 06/20/2007, Updated: 03/19/2009) - The drug gabapentin (Neurontin®) effectively reduced the intensity and duration of hot flashes in a clinical trial of more than 200 men receiving hormonal treatment for their prostate cancer, according to findings presented at the 2007 ASCO meeting in Chicago.
U.S. Cancer Screening Trial Shows No Early Mortality Benefit from Annual Prostate Cancer Screening
(Posted: 03/18/2009) - Six annual screenings for prostate cancer led to more diagnoses of the disease, but no fewer prostate cancer deaths, according to a major new report from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, a 17-year project of the NCI. The PLCO was designed to provide answers about the effectiveness of prostate cancer screening.